D-Dimer Levels Over Time and The Risk Of Recurrent Venous Thromboembolism: An Update Of The Vienna Prediction Model

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 462-462
Author(s):  
Sabine Eichinger ◽  
Georg Heinze ◽  
Paul A Kyrle

Background Patients with unprovoked venous thromboembolism (VTE) have a high recurrence risk and are candidates for extended anticoagulation. However, many patients stay recurrence free and are unnecessarily exposed to anticoagulants. The Vienna Prediction Model has been developed to discriminate patients with unprovoked VTE with a low recurrence risk from those with a high risk based on the patient’s sex, the location of VTE, and D-Dimer, but allows risk assessment only at one single time point (3 weeks after anticoagulation). Aim To update and expand the model based on a larger number of events and a longer observation time, in order to assess the recurrence risk also from time points later than three weeks after anticoagulation on. Methods We analysed the data set of the Austrian Study on Recurrent Venous Thromboembolism, a prospective cohort study in patients of legal age with a first VTE who had received anticoagulants for 3 to 18 months. Patients with VTE provoked by surgery, trauma, pregnancy, or female hormone intake; with a natural inhibitor deficiency, the lupus anticoagulant, or cancer were excluded. The study end point was recurrent symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE). We integrated D-Dimer levels measured at several time points after anticoagulation with the patient’s sex and location of VTE. We generated nomograms to calculate individual risk scores and cumulative recurrence rates from 3 weeks, 3, 9, and 15 months on after discontinuation of anticoagulation using a dynamic landmark competing risks regression approach. The ethics committee approved the study and all patients gave written informed consent. Results 134 of 553 patients had recurrence during a mean follow-up of 6 years. D-Dimer levels varied between patients, but did not substantially - albeit statistical significantly (p<0.001) - increase over time. The updated model has two improvements: we accounted for the competing risk of death or informative drop out by competing risks regression, and we considered various time points of prediction rather than predicting just once after anticoagulation. Subdistribution hazard ratios (95% CI) dynamically changed from 3 weeks to 3, 9, and 15 months from 2.4 (1.6-3.8), 2.3 (1.5-3.5), 2.0 (1.3-3.0) to 1.7 (1.1-2.7) in men vs. women, from 1.8 (1.0-3.4), 1.7 (0.9-3.1), 1.5 (0.8-2.8) to 1.4 (0.8-2.7) in patients with proximal DVT or PE compared to distal DVT, and from 1.3 (1.1-1.6), 1.3 (1.1-1.5), 1.2 (1.0-1.4) to 1.1 (0.9-1.4) per doubling D-Dimer levels. We created nomograms based on subdistribution hazard ratios from the multivariable dynamic model to predict the recurrence risk from 3 weeks, 3, 9 or 15 months on after anticoagulation. A web-based calculator allows risk assessment from random time points on between 3 weeks and 15 months. Conclusions The updated Vienna Prediction Model integrates patient’s sex, location of first VTE and serial D-Dimer measurements and allows prediction of recurrent VTE at a random time point after discontinuation of oral anticoagulation. Disclosures: No relevant conflicts of interest to declare.

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2493 ◽  
Author(s):  
Florian Moik ◽  
Nick van Es ◽  
Florian Posch ◽  
Marcello Di Nisio ◽  
Thorsten Fuereder ◽  
...  

Gemcitabine and platinum-based agents could increase the risk of venous thromboembolism (VTE) in patients with cancer. We evaluated the additive predictive utility of these agents towards cancer-associated VTE beyond a recently developed and externally validated clinical prediction model, which was based on tumor entity and continuous D-dimer levels. Analysis was performed in the derivation cohort of this model, obtained from the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study (n = 1409). Patients were followed for the occurrence of VTE for a maximum of two years. Competing-risk analysis was performed to obtain cumulative incidences and to conduct between-group comparisons of VTE risk. Cumulative two-year incidences of VTE were not elevated with gemcitabine treatment (10.2% vs. 7.5%, p = 0.148), whereas they were higher for platinum-based therapy (11.6% vs. 5.9%, p < 0.001). In a multivariable analysis, adjusting for tumor site category and D-dimer, gemcitabine was not associated with increased risk of VTE (subdistribution hazard ratio (SHR) 0.82, 95% confidence interval (CI) 0.53–1.28, p = 0.390), whereas platinum-based therapy predicted for a numerically increased VTE risk (SHR 1.44, 95% CI 0.96–2.17, p = 0.080). Similar results were obtained in a sensitivity analysis (updated cohort, n = 1870). Our findings suggest limited additional value of chemotherapy for the prediction of cancer-associated VTE, beyond a validated clinical prediction model.


Author(s):  
Matteo Nicola Dario Di Minno ◽  
Ilenia Calcaterra ◽  
Antimo Papa ◽  
Roberta Lupoli ◽  
Alessandro Di Minno ◽  
...  

2003 ◽  
Vol 89 (02) ◽  
pp. 284-287 ◽  
Author(s):  
John Kuruvilla ◽  
Phil Wells ◽  
Bev Morrow ◽  
Karen MacKinnon ◽  
Michael Keeney ◽  
...  

SummaryThe natural history of initially positive D-dimers for venous thromboembolism is not known. If it returns to negative in the majority of patients, it would be potentially helpful to diagnose a recurrence. In this study, we prospectively measured D-dimer levels in outpatients with a diagnosis of venous thrombo-embolism. There were a total of 152 patients with an average age of 57. D-dimer results were performed at baseline and repeated at one week, one month and three months.At baseline 120 of 152 (79%) had a positive D-dimer result. Of those with an initially positive result, 80% were still positive at one week and 39% were still positive at one month. Finally at three months, 13% remained positive. Seven patients had recurrent events and all had persistently elevated D-dimers at one month. This study suggests that a persistently positive D-dimer result after one month of treatment may indicate a higher risk of recurrent venous thromboembolism. D-dimer testing for the diagnosis of recurrence of venous thromboembolism deserves further study.


2013 ◽  
Vol 33 (03) ◽  
pp. 211-217 ◽  
Author(s):  
S. Eichinger

SummaryDeciding on the optimal duration of anticoagulation is based on the risk of recurrent venous thromboembolism (VTE) and of bleeding during anticoagulation. The duration of anticoagulation should be at least three months since shorter courses double the recurrence rates.At three months anticoagulation can be stopped in patients with a VTE provoked by a transient risk factor, as the recurrence risk is expected to be lower than the bleeding risk during anticoagulation. Patients with unprovoked VTE are at higher risk of recurrence and prolonged anticoagulation is currently recommended.However, attempts are made to stratify these patients according to their recurrence risk and to identify those with a low recurrence risk who would not benefit from extended anticoagulation. Novel approaches to optimize the management of patients with unprovoked VTE are the use of prediction models which link clinical patient characteristics with laboratory testing to discriminate between patients with a low risk (who may discontinue anticoagulation) and those with high risk (in whom long term anticoagulation is justified). Moreover, new antithrombotic concepts including new oral anticoagulants or aspirin both of which potentially confer a lower bleeding risk and are more convenient for the patients have been explored for extended thromboprophylaxis.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2301-2301
Author(s):  
kiara Cristina Senger Zapponi ◽  
Luis Fernando Bittar ◽  
Bruna m Mazetto ◽  
Fernanda Dutra Santiago-Bassora ◽  
Fernanda A. Orsi ◽  
...  

Abstract Abstract 2301 Introduction: Venous Thromboembolism (VTE) is a multifactorial disease that affects 1:1000 individuals worldwide, with a recurrence rate of about 25% in 10 years. Although many risk factors for VTE are well defined, first presentation and recurrence depend, at least in part, on as yet unknown etiologic factors. Studies in animal models show a tight relation between inflammation and hemostasis, as well as the infiltration of neutrophils in the venous wall after the induction of venous thrombosis. Neutrophils also participate in different stages in the formation and resolution of venous thrombosis. Methods: In this study, we investigated the adhesive properties of neutrophils in VTE patients. We hypothesized that increased adhesive properties of these cells, either as an individual baseline characteristic or as an acquired alteration after a previous VTE episode, could be associated with the thrombotic process. The patient population consisted of 22 VTE patients (14F:8M; median age: 46.1 years) that had completed at least 6 months of oral anticoagulation. Twenty-two healthy volunteers matched to VTE patients by age, gender and ethnic background were used as controls. Neutrophil adhesion was measured by a static adhesion assay in triplicate. Peripheral blood was collected with heparin and neutrophils were separated on Histopaque® (Sigma-Aldrich, St. Louis, MO, USA). Isolated neutrophils (2.2×106 cells/ml) were allowed to adhere to fibronectin (FN)-coated 96-well plates (30 min, 37°C, 5%CO2). Non-adherent cells were then removed by washing and adherent cells calculated as the percentage of cells adhered, compared to a standard curve of known cell concentrations and using a colorimetric enzyme assay. Results are expressed as means ± standard error of mean (SEM) and were compared using the Mann-Whitney test. Results: Overall, adhesion of neutrophils from VTE patients (25.40% ±2.35) was not increased when compared to the control group (21.25%±1.20 p=0.2). However when only patients at a higher risk of recurrence (n=13) - here defined as the presence of elevated D-dimer (higher than 0.5mg/L) and residual vein thrombosis - were analyzed, a statistically significant increase in cell adhesion compared to matched controls was observed (26.70%±2.08 and 21.36%±1.26, respectively, p = 0.04). When these patients (higher recurrence risk; n=13) were compared to the remaining VTE patients (standard recurrence risk, n=9), a non significant increase in neutrophil adhesion was observed (26.70%±2.08 vs 23.51%±5.03 respectively, p=0.1). Conclusions: We demonstrate that neutrophil adhesion is increased in patients with VTE with characteristics associated with increased recurrence risk. In addition, we also observed a non-significant difference in neutrophil adhesion in these patients compared to other VTE patients. Our results suggest that the increased adhesive properties of neutrophils in VTE patients could play a role in the exacerbation of inflammation, and in the pathophysiology of VTE. Further studies are warranted to study whether neutrophil adhesiveness could be used as a biomarker of VTE recurrence. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document